212 related articles for article (PubMed ID: 36005013)
1. Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment.
Singh V; Sheikh A; Abourehab MAS; Kesharwani P
Biosensors (Basel); 2022 Aug; 12(8):. PubMed ID: 36005013
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy.
Park UB; Jeong TJ; Gu N; Lee HT; Heo YS
Biochem Biophys Res Commun; 2022 Apr; 599():31-37. PubMed ID: 35168061
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H; He X; Wang Q
Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
[TBL] [Abstract][Full Text] [Related]
4. An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer.
Bartoletti M; Giorda G; Viel A; Fornasarig M; Zdjelar A; Segatto E; Sorio R; Corsetti S; Scalone S; Nicoloso MS; Pivetta T; Lucia E; Clemente N; Palazzari E; Canzonieri V; Puglisi F
Curr Oncol; 2022 Jul; 29(8):5209-5212. PubMed ID: 35892982
[TBL] [Abstract][Full Text] [Related]
5. Dostarlimab: Review on success story and clinical trials.
Yadav R; Mathur I; Haokip HR; Pandey AK; Kumar V; Jain N
Crit Rev Oncol Hematol; 2024 Jun; 198():104374. PubMed ID: 38679402
[TBL] [Abstract][Full Text] [Related]
6. Promise of dostarlimab in cancer therapy: Advancements and cross-talk considerations.
Babar Q; Saeed A; Murugappan S; Dhumal D; Tabish T; Thorat ND
Drug Discov Today; 2023 Jun; 28(6):103577. PubMed ID: 37004983
[TBL] [Abstract][Full Text] [Related]
7. Dostarlimab: From preclinical investigation to drug approval and future directions.
Cicala CM; Musacchio L; Scambia G; Lorusso D
Hum Vaccin Immunother; 2023 Dec; 19(1):2178220. PubMed ID: 36762991
[TBL] [Abstract][Full Text] [Related]
8. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models.
Kumar S; Ghosh S; Sharma G; Wang Z; Kehry MR; Marino MH; Neben TY; Lu S; Luo S; Roberts S; Ramaswamy S; Danaee H; Jenkins D
MAbs; 2021; 13(1):1954136. PubMed ID: 34313545
[TBL] [Abstract][Full Text] [Related]
9. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer.
Kasherman L; Ahrari S; Lheureux S
Future Oncol; 2021 Mar; 17(8):877-892. PubMed ID: 33251877
[TBL] [Abstract][Full Text] [Related]
10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
11. Dostarlimab for the treatment of endometrium cancer and other solid tumors.
Rubio-Pérez J; Hernández R; Hernández T; Doger B; Casado V; Moreno V
Drugs Today (Barc); 2021 Mar; 57(3):187-197. PubMed ID: 33729216
[TBL] [Abstract][Full Text] [Related]
12. An Integrated Analysis of Dostarlimab Immunogenicity.
Lu S; Bowsher RR; Clancy A; Rosen A; Zhang M; Yang Y; Koeck K; Gao M; Potocka E; Guo W; Jen KY; Im E; Milton A
AAPS J; 2021 Jul; 23(5):96. PubMed ID: 34324079
[TBL] [Abstract][Full Text] [Related]
13. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action.
Willsmore ZN; Coumbe BGT; Crescioli S; Reci S; Gupta A; Harris RJ; Chenoweth A; Chauhan J; Bax HJ; McCraw A; Cheung A; Osborn G; Hoffmann RM; Nakamura M; Laddach R; Geh JLC; MacKenzie-Ross A; Healy C; Tsoka S; Spicer JF; Josephs DH; Papa S; Lacy KE; Karagiannis SN
Eur J Immunol; 2021 Mar; 51(3):544-556. PubMed ID: 33450785
[TBL] [Abstract][Full Text] [Related]
14. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Pennock GK; Chow LQ
Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and exposure-response of anti-programmed cell death protein-1 monoclonal antibody dostarlimab in advanced solid tumours.
Melhem M; Hanze E; Lu S; Alskär O; Visser S; Gandhi Y
Br J Clin Pharmacol; 2022 Sep; 88(9):4142-4154. PubMed ID: 35357027
[TBL] [Abstract][Full Text] [Related]
16. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial.
Oaknin A; Tinker AV; Gilbert L; Samouëlian V; Mathews C; Brown J; Barretina-Ginesta MP; Moreno V; Gravina A; Abdeddaim C; Banerjee S; Guo W; Danaee H; Im E; Sabatier R
JAMA Oncol; 2020 Nov; 6(11):1766-1772. PubMed ID: 33001143
[TBL] [Abstract][Full Text] [Related]
17. Dostarlimab: A Review.
Costa B; Vale N
Biomolecules; 2022 Jul; 12(8):. PubMed ID: 35892341
[TBL] [Abstract][Full Text] [Related]
18. Dostarlimab: First Approval.
Markham A
Drugs; 2021 Jul; 81(10):1213-1219. PubMed ID: 34106455
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.
Moreno V; Roda D; Pikiel J; Trigo J; Bosch-Barrera J; Drew Y; Kristeleit R; Hiret S; Bajor DL; Cruz P; Beck JT; Ghosh S; Dabrowski C; Antony G; Duan T; Veneris J; Zografos E; Subramanian J
Clin Lung Cancer; 2022 Nov; 23(7):e415-e427. PubMed ID: 35729005
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PD-1 pathway: a promising future for the treatment of melanoma.
Mamalis A; Garcha M; Jagdeo J
Arch Dermatol Res; 2014 Aug; 306(6):511-9. PubMed ID: 24615548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
